<DOC>
	<DOCNO>NCT00408447</DOCNO>
	<brief_summary>Sickle cell disease genetic disorder mutation beta chain human hemoglobin result abnormal blood hemoglobin , cause red blood cell sickle stress result symptom include severe pain stroke . Beta thalassemia another genetic disorder abnormal beta hemoglobin chain , cause anemia . In disorder , frequent red blood cell transfusion may require sustain life , often result complication include multiple hospitalization , iron overload , bacterial viral infection hepatitis . Standard drug therapy use treatment sickle cell disease and/or beta thalassemia provide supportive care , may result long-term side effect , inadequate control disease process . Bone marrow transplant increasingly use long-term treatment cure sickle cell disease beta thalassemia . Although , without acute potential long term side effect , alternative offer long term control potential cure disease . Most side effect see bone marrow transplant directly relate high intensity chemotherapy use ( ablative ) . The primary purpose study see give low dos chemotherapy ( moderately ablative ) result successful bone marrow replacement without severe side-effects permanent control disease . Patients receive chemotherapy regimen busulfan , fludarabine , alemtuzumab follow infusion stem cell , either family-related cord-blood match donor .</brief_summary>
	<brief_title>Stem Cell Transplant Sickle Cell Disease Thalassemia</brief_title>
	<detailed_description>Further study detail provide Columbia University , Division Pediatric Blood &amp; Marrow Transplantation . STUDY DESIGN : Patients receive busulfan , fludarabine alemtuzumab prior stem cell transplant help stem cell take grow . The stem cell infuse day 0 intravenous catheter . Patients receive immunosuppressive therapy tacrolimus MMF prevent graft-versus-disease . Patients follow transplant look special cell blood show new bone marrow take hold ( engraft ) . Response shall document 6 month , 1 year , 2 year 3 year post-SCT .</detailed_description>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>beta-Thalassemia</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>Sickle Cell Disease : Diagnosis Homozygous Hemoglobin S Disease Heterozygous Hemoglobin SC S 0/+ thalassemia , Sickle/variant result Chronic Hemolytic Anemia HgB ≤10 mg/dL Age ≤30 Matched sibling donor asymptomatic , 8/8 HLA match unrelated adult donor Patient must adequate organ function : Adequate renal function define serum creatinine ≤1.5 x normal , Creatinine clearance radioisotope GFR &gt; 100 ml/min/1.73 m2 &gt; 70ml/min/1.73m2 patient &gt; 16 year old Adequate liver function define SGOT ( AST ) SGPT ( ALT ) &lt; 5.0 x normal Adequate Cardiac Function define shorten fraction ≥28 % echocardiogram , ejection fraction ≥48 % radionuclide angiogram echocardiogram Adequate pulmonary function define correct DLCO≥40 % pulmonary function test , child unable perform DLCO maneuver ≥85 % O2 saturation , evidence dyspnea rest Exclusion criterion : General Karnofsky/Lansky Performance Score &lt; 60 % Demonstrated lack compliance medical care Pregnant nursing Evidence uncontrolled bacterial , viral fungal infection ( currently take medication progression clinical symptom ) within 1 month prior start condition regimen . Patients fever suspect minor infection await resolution symptom start condition regimen . Histologic Exam Liver ( liver biopsy ) bridge fibrosis cirrhosis .</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>stem cell transplant</keyword>
	<keyword>sickle cell disease</keyword>
	<keyword>thalassemia</keyword>
	<keyword>moderately ablative</keyword>
	<keyword>cord blood transplant</keyword>
	<keyword>match family donor</keyword>
</DOC>